(CE) Celanese - Overview
Sector: Basic Materials | Industry: Chemicals | Exchange: NYSE (USA) | Market Cap: 5.745m USD | Total Return: -2.3% in 12m
Avg Turnover: 119M
EPS Trend: -87.7%
Qual. Beats: 0
Rev. Trend: -88.3%
Qual. Beats: 0
Warnings
High Debt/EBITDA (33.7) with thin interest coverage (-0.6)
Interest Coverage Ratio -0.6 is critical
Below Avwap Earnings
Tailwinds
Confidence
Celanese Corporation (NYSE: CE) is a global chemical and specialty materials company headquartered in Irving, Texas. It operates primarily through two segments: Engineered Materials and the Acetyl Chain. The company produces a wide array of high-performance polymers, resins, and acetyl products used in diverse end-markets, including automotive, healthcare, consumer electronics, and industrial construction.
As a key player in the specialty chemicals sector, Celanese utilizes a vertically integrated business model, particularly within its Acetyl Chain, which converts raw materials like carbon monoxide and methanol into base chemicals and derivative products. This integration allows for greater cost efficiency and supply chain stability compared to non-integrated competitors. The specialty chemicals industry is characterized by high barriers to entry due to the technical complexity of polymer formulations and the capital-intensive nature of chemical manufacturing plants.
The company maintains an extensive portfolio of established brands, such as Santoprene, Zytel, and GUR, selling directly to original equipment manufacturers (OEMs) and through global distribution networks. For a deeper look into the companys valuation metrics and historical performance, you may find it useful to explore the data on ValueRay. Founded in 1912, Celanese has evolved from a regional manufacturer into a global supplier of essential chemical building blocks and advanced engineering plastics.
- Global methanol and acetic acid price volatility impacts Acetyl Chain margins
- Automotive and electronics demand cycles dictate Engineered Materials revenue growth
- High debt leverage from M&A activity influences credit ratings and valuation
- Raw material cost fluctuations for ethylene and natural gas affect profitability
- Expansion into high-margin medical and green technology sectors drives long-term growth
| Net Income: -1.09b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 2.18 > 1.0 |
| NWC/Revenue: 17.41% < 20% (prev 26.06%; Δ -8.64% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.19b > Net Income -1.09b |
| Net Debt (11.1b) to EBITDA (331.0m): 33.68 < 3 |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (110.0m) vs 12m ago 0.55% < -2% |
| Gross Margin: 19.83% > 18% (prev 0.23%; Δ 1.96k% > 0.5%) |
| Asset Turnover: 42.25% > 50% (prev 43.36%; Δ -1.11% > 0%) |
| Interest Coverage Ratio: -0.61 > 6 (EBITDA TTM 331.0m / Interest Expense TTM 751.0m) |
| A: 0.08 (Total Current Assets 5.97b - Total Current Liabilities 4.32b) / Total Assets 21.7b |
| B: 0.46 (Retained Earnings 9.92b / Total Assets 21.7b) |
| C: -0.02 (EBIT TTM -455.0m / Avg Total Assets 22.5b) |
| D: 0.53 (Book Value of Equity 9.11b / Total Liabilities 17.2b) |
| Altman-Z'' = 2.40 = A |
| DSRI: 1.44 (Receivables 1.68b/1.24b, Revenue 9.49b/10.1b) |
| GMI: 1.14 (GM 19.83% / 22.65%) |
| AQI: 0.95 (AQ_t 0.50 / AQ_t-1 0.52) |
| SGI: 0.94 (Revenue 9.49b / 10.1b) |
| TATA: -0.10 (NI -1.09b - CFO 1.19b) / TA 21.7b) |
| Beneish M = -2.72 (Cap -4..+1) = A |
As of May 30, 2026, the stock is trading at USD 53.13 with a total of 907,045 shares traded.
Over the past week, the price has changed by +0.43%,
over one month by -18.37%,
over three months by +6.44% and
over the past year by -2.31%.
Celanese has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy CE.
- StrongBuy: 8
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 74.6 | 40.3% |
P/E Forward = 8.7336
P/S = 0.6053
P/B = 1.414
P/EG = 4.4198
Revenue TTM = 9.49b USD
EBIT TTM = -455.0m USD
EBITDA TTM = 331.0m USD
Long Term Debt = 10.8b USD (from longTermDebt, last quarter)
Short Term Debt = 1.74b USD (from shortTermDebt, last quarter)
Debt = 12.9b USD (from shortLongTermDebtTotal, last quarter) + Leases 351.0m
Net Debt = 11.1b USD (calculated: Debt 12.9b - CCE 1.76b)
Enterprise Value = 16.9b USD (5.75b + Debt 12.9b - CCE 1.76b)
Interest Coverage Ratio = -0.61 (Ebit TTM -455.0m / Interest Expense TTM 751.0m)
EV/FCF = 17.89x (Enterprise Value 16.9b / FCF TTM 944.0m)
FCF Yield = 5.59% (FCF TTM 944.0m / Enterprise Value 16.9b)
FCF Margin = 9.95% (FCF TTM 944.0m / Revenue TTM 9.49b)
Net Margin = -11.54% (Net Income TTM -1.09b / Revenue TTM 9.49b)
Gross Margin = 19.83% ((Revenue TTM 9.49b - Cost of Revenue TTM 7.61b) / Revenue TTM)
Gross Margin QoQ = 18.96% (prev 17.38%)
Tobins Q-Ratio = 0.78 (Enterprise Value 16.9b / Total Assets 21.7b)
Interest Expense / Debt = 5.82% (Interest Expense 751.0m / Debt 12.9b)
Taxrate = 40.24% (33.0m / 82.0m)
NOPAT = -271.9m (EBIT -455.0m * (1 - 40.24%)) [loss with tax shield]
Current Ratio = 1.38 (Total Current Assets 5.97b / Total Current Liabilities 4.32b)
Debt / Equity = 3.18 (Debt 12.9b / totalStockholderEquity, last quarter 4.06b)
Debt / EBITDA = 33.68 (Net Debt 11.1b / EBITDA 331.0m)
Debt / FCF = 11.81 (Net Debt 11.1b / FCF TTM 944.0m)
Total Stockholder Equity = 4.34b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.87% (Net Income -1.09b / Total Assets 21.7b)
RoE = -25.26% (Net Income TTM -1.09b / Total Stockholder Equity 4.34b)
RoCE = -3.00% (EBIT -455.0m / Capital Employed (Equity 4.34b + L.T.Debt 10.8b))
RoIC = -1.43% (negative operating profit) (NOPAT -271.9m / Invested Capital 19.1b)
WACC = 5.31% (E(5.75b)/V(18.7b) * Re(9.42%) + D(12.9b)/V(18.7b) * Rd(5.82%) * (1-Tc(0.40)))
Discount Rate = 9.42% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 53.94 | Cagr: 0.20%
[DCF] Terminal Value 77.97% ; FCFF base≈767.2m ; Y1≈879.5m ; Y5≈1.29b
[DCF] Fair Price = 75.97 (EV 19.5b - Net Debt 11.1b = Equity 8.33b / Shares 109.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -87.75 | EPS CAGR: -26.84% | SUE: -0.13 | # QB: 0
Revenue Correlation: -88.26 | Revenue CAGR: -4.52% | SUE: -0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.24 | Chg30d=+54.55% | Revisions=+67% | Analysts=15
EPS next Quarter (2026-09-30): EPS=1.84 | Chg30d=+6.07% | Revisions=+44% | Analysts=15
EPS current Year (2026-12-31): EPS=6.14 | Chg30d=+16.14% | Revisions=+67% | GrowthEPS=+54.2% | GrowthRev=+5.8%
EPS next Year (2027-12-31): EPS=6.63 | Chg30d=+5.10% | Revisions=+38% | GrowthEPS=+8.0% | GrowthRev=+0.8%
[Analyst] Revisions Ratio: +67%